Pharma News

Dr. Reddy’s Laboratories Ltd. announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries.

The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.

CDSCO reported top brands of paracetamol, pantoprazole, amoxicillin and other amongst failed samples reported by CDSCO. These samples are reported to be not of standard quality. Total 59 different brands from well known pharmaceutical industries failed to compile with standard quality.

Top brands like Clavam 625, Mexclav 625, Shelcal, Pan D failed various assays and quality tests, which were collected and tested by different Drugs Testing Laboratories.

The U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age.